

< [Go to News Explorer](#)



RNS Issue of Equity

[Share this article](#)



## Issue of Equity & Total Voting Rights

### **IDEAGEN PLC**

Released 17:15:09 16 February 2021

RNS Number : 3043P  
Ideagen PLC  
16 February 2021

### **Ideagen PLC** ("Ideagen," "the Company" or the "Group")

#### **Issue of new shares under the Share Incentive Plan and Total Voting Rights**

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management Software to highly regulated industries, announces that it has allotted a total of 3,023 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") following the purchase of 3,023 Ordinary Shares by a number of employees under the Company's Share Incentive Plan ("SIP").

Application has been made to the London Stock Exchange for the 3,023 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 22 February 2021.

After Admission, the total number of Ordinary Shares in issue will be 252,125,074 and the total number of voting rights will therefore be 252,125,074. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

#### **Enquiries:**

**Ideagen plc** **01629 699 100**  
David Hornsby, Executive Chairman  
Ben Dorks, Chief Executive Officer  
Emma Hayes, Chief Financial Officer

**finnCap Limited** **020 7220 0500**  
Henrik Persson/James Thompson (Nomad)  
Alice Lane (ECM)

**Canaccord Genuity** **020 7523 8000**  
Simon Bridges  
Richard Andrews

#### **About Ideagen plc**

Ideagen is a UK-headquartered, global technology company quoted on the London Stock Exchange AIM market (Ticker: IDEAL).

A global supplier of regulatory and compliance solutions, Ideagen provides a common software platform and an integrated risk-based approach to meet multi-industry standards, enabling compliance with relevant laws, policies, and regulations.

The Group provides software and services to organisations operating within highly regulated industries such as life sciences, healthcare, banking and finance, insurance, aviation, and aerospace and defence, with its main operational premises spread throughout the UK, EU, US, Middle East and SE Asia.

Currently, more than 5,700 organisations use Ideagen's products including eight of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of the world's leading pharmaceutical firms.

Ideagen's diverse and varied customer base includes many well-known, global brands such as British Airways, Aggreko, BAE, Ryanair, US Navy, KLM, BBVA, Bank of New York, Commerzbank, Meggitt, Heineken, Johnson Matthey, Haeco Group and European Central Bank. As well as this, Ideagen counts 250 hospitals across the UK and US amongst its client base. For further information please visit [www.ideagen.com](http://www.ideagen.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEGPUGUPPGGMQ

**London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.**